This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
這位康耐視分析師不再看好;以下是週二的前5個降級
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
華爾街頂級分析師改變了對這些頂級公司的展望。如需查看包括升級和降級在內的所有分析師評級變化的完整視圖,請參閱我們的分析師評級頁面。
- Deutsche Bank analyst Bryan Keane downgraded the rating for Marqeta, Inc. (NASDAQ:MQ) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. See how other analysts view this stock.
- Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:CGNX) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. See how other analysts view this stock.
- JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:SANA) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. See how other analysts view this stock.
- JP Morgan analyst Tessa Romero downgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. See how other analysts view this stock.
- Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. See how other analysts view this stock.
- 德意志銀行分析師Bryan Keane將Marqeta, Inc. (納斯達克:MQ)的評級從買入降級爲持有,並將價格目標從$9降至$4。Marqeta股價週一收盤價爲$5.95。看看其他分析師如何看待這隻股票。
- Truist證券分析師Jamie Cook將Cognex Corporation (納斯達克:CGNX)的評級從買入降級爲持有,並將價格目標從$46下調至$43。Cognex股價週一收盤價爲$40.85。看看其他分析師如何看待這隻股票。
- JMP證券分析師Reni Benjamin將Sana Biotechnology, Inc. (納斯達克:SANA)的評級從市場表現優異降級爲市場表現。Sana Biotechnology股價週一收盤價爲$3.76。看看其他分析師如何看待這隻股票。
- 摩根大通分析師Tessa Romero將Neumora Therapeutics, Inc. (納斯達克:NMRA)的評級從超重降級爲中立,並將價格目標從$18下調至$15。Neumora Therapeutics股價週一收盤價爲$11.71。看看其他分析師如何看待這隻股票。
- Leerink Partners分析師Christopher Liu將IDEAYA Biosciences, Inc. (納斯達克:IDYA)的評級從表現優異降級爲市場表現,並將價格目標從$41下調至$27。IDEAYA Biosciences股價週一收盤價爲$30.00。看看其他分析師如何看待這隻股票。
Considering buying CGNX stock? Here's what analysts think:
考慮購買CGNX股票嗎?以下是分析師的看法:
Read This Next:
Read This Next:
- Top 3 Health Care Stocks You'll Regret Missing In November
- 11月你會後悔錯過的前三家醫療保健股票